Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target ...
Catalyst Pharmaceuticals (NASDAQ:CPRX) raises FY2025 sales outlook from $545.000 million-$565.000 million to $565.000 million-$...
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical co...
Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.000 million-$565.000 million to $545.000 million-...
